OXB, a U.K.-based cell and gene therapy manufacturer, expanded its ongoing partnership with Bristol Myers Squibb to supply lentiviral vectors for the pharma giant’s CAR-T programs. The newly expanded ...
Viral Vector Manufacturing Facility Pty Ltd (VVMF), Australia’s first commercial viral vector Contract Development and Manufacturing Organisation (CDMO), today announces that it has entered into a ...
OXB to become commercial manufacturer of lentiviral vectors for Bristol Myers Squibb (BMS) CAR-T programmes Multi-year agreement with five-year initial term and option to extend Oxford, UK – 4 ...
Progression to full ownership aligns with global strategy and supports long-term growth in the viral vector manufacturing market Oxford, UK – 23 June 2025: OXB (LSE: OXB) (“the Company”), a global ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results